All Oncology News

OncLive proudly announces the 2015 Giants of Cancer Care, a dozen medical pioneers recognized by a panel of eminent oncologists for landmark achievements that have changed the course of cancer treatment. Honorees will be introduced and celebrated at the 3rd Annual Giants of Cancer Care Award Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating Company.

The Chemotherapy Foundation Symposium, one of the largest oncology/hematology-focused conferences in the United States, was acquired last week by Physicians' Education Resource (PER) Events, LLC.

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

At a recent FDA joint advisory committee meeting, members voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec as a treatment for patients with advanced melanoma.

New England Journal of Medicine Publishes Study Co-Led by Hollings Cancer Center Researcher Showing Potential of New Genomic Test In Lung Screening.

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.

In a recent interview with AJHO, Sara A. Hurvitz, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer and what the future might hold.

ASCO has proposed a series of payment reforms that it says would significantly increase physician pay and the breadth of patient services available while lowering the overall cost of cancer care.

Patients with diffuse large B-cell lymphoma who developed detectable circulating tumor DNA during surveillance were more than 200 times more likely to have their disease progress than those who did not have detectable ctDNA.

Oncologists whose research and treatment innovations have changed the course of cancer care will join the elite roster of medical pioneers named OncLive's Giants of Cancer Care when the 2015 honorees are announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

Addition of renowned multi-tumor cancer conference augments PER's robust portfolio of continuing medical education offerings in oncology.

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.

By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.

Josep Tabernero, MD, PhD, discusses the potential of the antibody mixture Sym004 in mCRC, as well as other emerging trends in the management of colorectal cancer.

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

Individuals chosen by this elite committee to receive the 2015 Giants of Cancer Care award for outstanding contributions in the field of oncology will be announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

While some patients with Hodgkin lymphoma require radiotherapy, the risks are not necessary for a large portion of patients who can experience long-term disease-free survival with chemotherapy alone, says John Radford, MD.

In an interview with OncLive, Charles M. Perou, MD, explains the importance of understanding and treating each subtype differently and why oncologists should be aware of the similarities between basal-like breast cancer and other non-breast cancer tumor types.

The first FDA-approved biosimilar, Zarxio, has been blocked from reaching US markets by an injunction from Amgen, the manufacturer of the G-CSF analog counterpart, Neupogen (filgrastim).

The FDA has granted a breakthrough therapy designation to the Bcl-2 inhibitor venetoclax (GDC-0199/ABT-199) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who harbor a 17p deletion (del[17p]).

Earlier diagnosis, longer treatment durations, and increased effectiveness of treatments helped to boost spending on cancer medicines to the $100 billion threshold in 2014, a rise of 10.3% for the year, and up markedly from $75 billion five years earlier.

In an interview with OncLive, Robert C. Bast, Jr, MD, discussed his research using CA-125 levels and p53-autoantibodies as biomarkers for early detection of ovarian cancer.

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for previously untreated patients with unresectable or metastatic melanoma.

Deliberations are complete and final votes cast for the winners of the 2015 Giants of Cancer Care Award recognizing individuals who have achieved landmark success in the field of oncology.

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.

To gain further insight into the impact of ibrutinib and idelalisib, as well as other emerging therapies and treatment strategies in CLL, OncLive sat down with Steven Coutre, MD, at the AACR meeting,

Treatment with ofatumumab plus fludarabine and cyclophosphamide significantly improved progression-free survival compared with fludarabine and cyclophosphamide alone in patients with relapsed chronic lymphocytic leukemia.

Black/African-American women had a significantly higher absolute area breast density of 40.1 cm2 compared with 33.1 cm2 in white women.